INR 73.78
(3.49%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 46.15 Million INR | 7.39% |
2022 | 336 Million INR | -7.49% |
2021 | 363.22 Million INR | 285.76% |
2020 | 94.15 Million INR | -32.66% |
2019 | 139.82 Million INR | 6.38% |
2018 | 131.43 Million INR | 8.87% |
2017 | 120.72 Million INR | -2.4% |
2016 | 123.7 Million INR | -1.71% |
2015 | 125.85 Million INR | 0.0% |
2014 | - INR | 0.0% |
2011 | 412.24 Million INR | 28.75% |
2010 | 320.19 Million INR | 38.41% |
2009 | 231.34 Million INR | 19.07% |
2008 | 194.29 Million INR | -8.1% |
2007 | 211.41 Million INR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 95.78 Million INR | 15.14% |
2023 Q4 | 83.19 Million INR | -46.4% |
2023 FY | 360.84 Million INR | 7.39% |
2023 Q2 | 154.47 Million INR | 6.62% |
2023 Q1 | 144.89 Million INR | 1957.34% |
2023 Q3 | 155.2 Million INR | 0.47% |
2022 Q3 | 121.4 Million INR | 8.87% |
2022 Q2 | 111.51 Million INR | 0.57% |
2022 Q1 | 110.88 Million INR | 71.2% |
2022 FY | 336 Million INR | -7.49% |
2022 Q4 | -7.8 Million INR | -106.43% |
2021 Q3 | 175.79 Million INR | 25.34% |
2021 Q2 | 140.25 Million INR | 236.65% |
2021 Q4 | 64.76 Million INR | -63.16% |
2021 FY | 363.22 Million INR | 285.76% |
2021 Q1 | 41.66 Million INR | 15.44% |
2020 Q3 | 27.52 Million INR | 710.09% |
2020 FY | 94.15 Million INR | -32.66% |
2020 Q4 | 36.08 Million INR | 31.1% |
2020 Q1 | 23.73 Million INR | -18.7% |
2020 Q2 | 3.39 Million INR | -85.68% |
2019 Q4 | 29.19 Million INR | -18.97% |
2019 FY | 139.82 Million INR | 6.38% |
2019 Q1 | 39.34 Million INR | 7.1% |
2019 Q2 | 42.27 Million INR | 7.45% |
2019 Q3 | 36.03 Million INR | -14.78% |
2018 Q2 | 25.16 Million INR | -11.36% |
2018 Q1 | 28.38 Million INR | -60.25% |
2018 FY | 131.43 Million INR | 8.87% |
2018 Q4 | 36.73 Million INR | -10.73% |
2018 Q3 | 41.15 Million INR | 63.55% |
2017 Q3 | 15.32 Million INR | -54.76% |
2017 Q1 | 28.91 Million INR | -22.36% |
2017 Q4 | 71.41 Million INR | 365.91% |
2017 FY | 120.72 Million INR | -2.4% |
2017 Q2 | 33.88 Million INR | 17.17% |
2016 Q2 | 33.25 Million INR | 36.03% |
2016 FY | 123.7 Million INR | -1.71% |
2016 Q3 | 31.12 Million INR | -6.41% |
2016 Q1 | 24.44 Million INR | -13.9% |
2016 Q4 | 37.24 Million INR | 19.65% |
2015 Q1 | 29.83 Million INR | 0.0% |
2015 FY | 125.85 Million INR | 0.0% |
2015 Q2 | 20.88 Million INR | -30.02% |
2015 Q3 | 23.37 Million INR | 11.96% |
2015 Q4 | 28.39 Million INR | 21.46% |
2014 FY | - INR | 0.0% |
2014 Q3 | 13.98 Million INR | 0.0% |
2013 Q2 | 18.19 Million INR | 0.0% |
2013 Q3 | 20.98 Million INR | 15.37% |
2012 Q3 | 49.98 Million INR | 15.44% |
2012 Q2 | 43.29 Million INR | 0.0% |
2011 Q3 | 107.32 Million INR | 3.02% |
2011 FY | 412.24 Million INR | 28.75% |
2011 Q4 | 102.51 Million INR | -4.48% |
2011 Q2 | 104.18 Million INR | 0.0% |
2010 FY | 320.19 Million INR | 38.41% |
2009 FY | 231.34 Million INR | 19.07% |
2008 FY | 194.29 Million INR | -8.1% |
2008 Q4 | 55.66 Million INR | 0.0% |
2007 FY | 211.41 Million INR | 0.0% |
2007 Q4 | 51.77 Million INR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 99.97% |
NATCO Pharma Limited | 10.05 Billion INR | 99.541% |
Suven Pharmaceuticals Limited | 1.4 Billion INR | 96.71% |
Syncom Formulations (India) Limited | 942.39 Million INR | 95.102% |
Achyut Healthcare Limited | 1.6 Million INR | -2768.614% |
Ajanta Pharma Limited | 30.46 Billion INR | 99.848% |
Alkem Laboratories Limited | 32.83 Billion INR | 99.859% |
Alpa Laboratories Limited | 156.14 Million INR | 70.441% |
Alembic Pharmaceuticals Limited | 15.86 Billion INR | 99.709% |
AstraZeneca Pharma India Limited | 2.6 Billion INR | 98.225% |
Aurobindo Pharma Limited | 39.23 Billion INR | 99.882% |
Bajaj HealthCare Limited | 985.34 Million INR | 95.316% |
Bliss GVS Pharma Limited | 1.41 Billion INR | 96.748% |
Brooks Laboratories Limited | 51.18 Million INR | 9.816% |
Divi's Laboratories Limited | 14.17 Billion INR | 99.674% |
Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 99.952% |
Eris Lifesciences Limited | 4.94 Billion INR | 99.066% |
FDC Limited | 5.34 Billion INR | 99.137% |
Glenmark Pharmaceuticals Limited | 67.56 Billion INR | 99.932% |
Glenmark Life Sciences Limited | 11.64 Billion INR | 99.603% |
Granules India Limited | 7.18 Billion INR | 99.357% |
Gufic Biosciences Limited | 1.07 Billion INR | 95.717% |
Hester Biosciences Limited | 908.84 Million INR | 94.921% |
Indoco Remedies Limited | 4.74 Billion INR | 99.028% |
Ind-Swift Laboratories Limited | 2.12 Billion INR | 97.827% |
Ipca Laboratories Limited | 13.91 Billion INR | 99.668% |
Jagsonpal Pharmaceuticals Limited | 773.41 Million INR | 94.032% |
Lasa Supergenerics Limited | 291.17 Million INR | 84.148% |
Laurus Labs Limited | 3.01 Billion INR | 98.467% |
Lupin Limited | 95.67 Billion INR | 99.952% |
Mankind Pharma Limited | 23.15 Billion INR | 99.801% |
Medicamen Biotech Limited | 335.16 Million INR | 86.229% |
Medico Remedies Limited | 161.84 Million INR | 71.481% |
Megasoft Limited | 49.52 Million INR | 6.808% |
Piramal Pharma Limited | 19.91 Billion INR | 99.768% |
RPG Life Sciences Limited | 1.63 Billion INR | 97.178% |
Sigachi Industries Limited | 579.88 Million INR | 92.041% |
Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | 98.5% |
Unichem Laboratories Limited | 6.72 Billion INR | 99.314% |
Wanbury Limited | 1.16 Billion INR | 96.024% |
Windlas Biotech Limited | 1 Billion INR | 95.414% |
ZIM Laboratories Limited | 1.01 Billion INR | 95.444% |
Zydus Lifesciences Limited | 43.17 Billion INR | 99.893% |
Procter & Gamble Health Limited | 2.99 Billion INR | 98.459% |
Amrutanjan Health Care Limited | 1.09 Billion INR | 95.8% |
Bal Pharma Limited | 389.89 Million INR | 88.162% |
Strides Pharma Science Limited | 9.16 Billion INR | 99.496% |
Venus Remedies Limited | 1.91 Billion INR | 97.591% |
Aarti Pharmalabs Limited | 3.07 Billion INR | 98.499% |
Nectar Lifesciences Limited | 625.55 Million INR | 92.622% |
Shilpa Medicare Limited | 2.18 Billion INR | 97.883% |
Aarti Drugs Limited | 1.16 Billion INR | 96.047% |
IOL Chemicals and Pharmaceuticals Limited | 1.09 Billion INR | 95.799% |
Suven Life Sciences Limited | 109.75 Million INR | 57.944% |
Ind-Swift Limited | 946.56 Million INR | 95.124% |
Valiant Laboratories Limited | 36.28 Million INR | -27.19% |
J. B. Chemicals & Pharmaceuticals Limited | 8.41 Billion INR | 99.452% |
Solara Active Pharma Sciences Limited | 4.57 Billion INR | 98.992% |
Themis Medicare Limited | 782.85 Million INR | 94.104% |
Hikal Limited | 2.48 Billion INR | 98.144% |
Torrent Pharmaceuticals Limited | 21.42 Billion INR | 99.785% |
Sequent Scientific Limited | 2.9 Billion INR | 98.409% |
Novartis India Limited | 470.1 Million INR | 90.182% |
Wockhardt Limited | 6.4 Billion INR | 99.279% |
Jubilant Pharmova Limited | 14.45 Billion INR | 99.681% |
Biofil Chemicals and Pharmaceuticals Limited | 16.2 Million INR | -184.743% |
Neuland Laboratories Limited | 2.92 Billion INR | 98.425% |
Morepen Laboratories Limited | 1.98 Billion INR | 97.678% |
Kilitch Drugs (India) Limited | 412.42 Million INR | 88.809% |
Mangalam Drugs & Organics Limited | 676.14 Million INR | 93.174% |